SVR12 in Genotype 3 HCV (F0-F2) Treated With RDV + SOF
Key facts
- Who runs it
- Center of target therapy
- Where
- Russia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 30 people enrolled
- Started
- 17 Sept 2025
- Ended
- 2 Feb 2026
- Type of study
- Observational
- Record updated
- 5 January 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Patient informed consent for the collection and use of data in scientific research
- Diagnosed chronic hepatitis C (genotype 3)
- Fibrosis stage F0-F2 according to METAVIR, confirmed by liver biopsy or liver elastography (results of performed studies must be no older than 3 months at the start of antiviral therapy)
- Signed informed consent
- Age ≥18 years
- Antiviral therapy with ravidasvir and sofosbuvir initiated as part of routine clinical practice
Who cannot take part
- Significant concomitant liver diseases considered relevant by the investigator (hepatitis B, hemochromatosis, autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hepatocellular carcinoma)
- If the patient has received other antiviral treatment for hepatitis C within the last 6 months
- Alcohol or drug dependence that may interfere with adherence to the treatment regimen
- Presence of other active viral infections (e.g., hepatitis B, HIV)
- Pregnancy or breastfeeding
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study will follow a group of people with chronic hepatitis C infection of genotype 3 who have mild to moderate liver fibrosis (stages F0-F2, measured by a liver stiffness test). All participants will be receiving the antiviral drugs ravidasvir and sofosbuvir as part of their regular medical care.
Read full original descriptionShow less
Only patients who start this treatment, meet the study's eligibility criteria, and give written consent for their medical data to be used in research will take part. They will be monitored during their routine clinic visits while receiving the two-drug therapy.
After 8 weeks of treatment, researchers will check how many patients have cleared the virus from their blood. Those who achieve this response will continue to be followed for another 4 and 12 weeks after treatment to see if the virus remains undetectable.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective, Single-cohort, Observational Clinical Study Evaluating the Rate of Achieving SVR12 in Patients With Chronic Hepatitis C Genotype 3 With Fibrosis Stage F0-F2 Who Received Ravidasvir + Sofosbuvir Therapy.
- Record updated
- 5 January 2026